

**Clinical trial results:****A Phase I/II, Multicenter, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Cobimetinib In Pediatric and Young Adult Patients with Previously Treated Solid Tumors****Summary**

EudraCT number	2014-004685-25
Trial protocol	NL IE DK GB DE ES IT FR
Global end of trial date	21 July 2021

**Results information**

Result version number	v2 (current)
This version publication date	24 March 2022
First version publication date	05 February 2022
Version creation reason	

**Trial information****Trial identification**

Sponsor protocol code	G029665
-----------------------	---------

**Additional study identifiers**

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02639546
WHO universal trial number (UTN)	-

Notes:

**Sponsors**

Sponsor organisation name	F. Hoffmann-La Roche AG
Sponsor organisation address	Grenzacherstrasse 124, Basel, Switzerland, CH4070
Public contact	F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, +41 616878333, global.trial_information@roche.com
Scientific contact	F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, +41 616878333, global.trial_information@roche.com

Notes:

**Paediatric regulatory details**

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMA-001425-PIP01-13
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	21 July 2021
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	21 July 2021
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To evaluate the Safety and Pharmacokinetics of Cobimetinib

Protection of trial subjects:

All study subjects were required to read and sign an Informed Consent Form.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	20 May 2016
Long term follow-up planned	Yes
Long term follow-up rationale	Efficacy
Long term follow-up duration	5 Years
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Germany: 3
Country: Number of subjects enrolled	Spain: 6
Country: Number of subjects enrolled	France: 15
Country: Number of subjects enrolled	United Kingdom: 10
Country: Number of subjects enrolled	Israel: 7
Country: Number of subjects enrolled	Italy: 1
Country: Number of subjects enrolled	United States: 14
Worldwide total number of subjects	56
EEA total number of subjects	25

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	41

Adolescents (12-17 years)	14
Adults (18-64 years)	1
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

The study was conducted at 17 centers in 7 countries.

### Pre-assignment

Screening details:

A total of 63 participants were screened, of which a total of 56 participants were enrolled. Tumor type was not a determinant of cohort assignment for the phase I portion of the study. The phase II portion of the study was restricted to participants with Low-Grade Glioma.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Phase I (Tablet) Cobimetinib (0.6 mg/kg)

Arm description:

Dose-Escalation: Participants received 0.6 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.

Arm type	Experimental
Investigational medicinal product name	Cobimetinib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Cobimetinib was administered orally once daily at a dose of 0.6 mg/kg.

<b>Arm title</b>	Phase I (Tablet) Cobimetinib (0.8 mg/kg)
------------------	------------------------------------------

Arm description:

Dose-Escalation: Participants received 0.8 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.

Arm type	Experimental
Investigational medicinal product name	Cobimetinib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Cobimetinib was administered orally once daily at a dose of 0.8 mg/kg.

<b>Arm title</b>	Phase I (Tablet) Cobimetinib (1 mg/kg)
------------------	----------------------------------------

Arm description:

Dose-Escalation: Participants received 1 milligram per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Cobimetinib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: Cobimetinib was administered orally once daily at a dose of 1 mg/kg.	
<b>Arm title</b>	Phase I (Suspension) Cobimetinib (0.6 mg/kg)
Arm description: Dose-Escalation: Participants received 0.6 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.	
Arm type	Experimental
Investigational medicinal product name	Cobimetinib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and solvent for oral suspension
Routes of administration	Oral use
Dosage and administration details: Cobimetinib was administered orally once daily at a dose of 0.6 mg/kg.	
<b>Arm title</b>	Phase I (Suspension) Cobimetinib (0.8 mg/kg)
Arm description: Dose-Escalation: Participants received 0.8 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.	
Arm type	Experimental
Investigational medicinal product name	Cobimetinib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and solvent for oral suspension
Routes of administration	Oral use
Dosage and administration details: Cobimetinib was administered orally once daily at a dose of 0.8 mg/kg.	
<b>Arm title</b>	Phase I (Suspension) Cobimetinib (1 mg/kg)
Arm description: Dose-Escalation: Participants received 1 milligram per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.	
Arm type	Experimental
Investigational medicinal product name	Cobimetinib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and solvent for oral suspension
Routes of administration	Oral use
Dosage and administration details: Cobimetinib was administered orally once daily at a dose of 1 mg/kg.	
<b>Arm title</b>	Phase I (Suspension) Cobimetinib (1.33 mg/kg)
Arm description: Dose-Escalation: Participants received 1.33 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.	
Arm type	Experimental

Investigational medicinal product name	Cobimetinib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and solvent for oral suspension
Routes of administration	Oral use

Dosage and administration details:

Cobimetinib was administered orally once daily at a dose of 1.33 mg/kg.

<b>Arm title</b>	Phase II (Suspension) Cobimetinib (1 mg/kg)
------------------	---------------------------------------------

Arm description:

Dose-Expansion: Participants received 1 milligram per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.

Arm type	Experimental
Investigational medicinal product name	Cobimetinib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and solvent for oral suspension
Routes of administration	Oral use

Dosage and administration details:

Cobimetinib was administered orally once daily at a dose of 1 mg/kg.

<b>Number of subjects in period 1</b>	Phase I (Tablet) Cobimetinib (0.6 mg/kg)	Phase I (Tablet) Cobimetinib (0.8 mg/kg)	Phase I (Tablet) Cobimetinib (1 mg/kg)
Started	6	6	6
Completed	0	0	0
Not completed	6	6	6
Withdrawal By Subject	2	2	1
Study Terminated By Sponsor	-	2	3
Death	2	2	1
Lost to follow-up	-	-	1
PI, physician decision; no response to trt.	2	-	-

<b>Number of subjects in period 1</b>	Phase I (Suspension) Cobimetinib (0.6 mg/kg)	Phase I (Suspension) Cobimetinib (0.8 mg/kg)	Phase I (Suspension) Cobimetinib (1 mg/kg)
Started	6	7	8
Completed	0	0	0
Not completed	6	7	8
Withdrawal By Subject	-	-	1
Study Terminated By Sponsor	4	4	3
Death	2	2	2
Lost to follow-up	-	1	1
PI, physician decision; no response to trt.	-	-	1

<b>Number of subjects in period 1</b>	Phase I (Suspension)	Phase II (Suspension)
---------------------------------------	-------------------------	--------------------------

	Cobimetinib (1.33 mg/kg)	Cobimetinib (1 mg/kg)
Started	5	12
Completed	0	0
Not completed	5	12
Withdrawal By Subject	2	1
Study Terminated By Sponsor	3	9
Death	-	-
Lost to follow-up	-	1
PI, physician decision; no response to trt.	-	1

## Baseline characteristics

<b>Reporting groups</b>	
Reporting group title	Phase I (Tablet) Cobimetinib (0.6 mg/kg)
Reporting group description: Dose-Escalation: Participants received 0.6 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.	
Reporting group title	Phase I (Tablet) Cobimetinib (0.8 mg/kg)
Reporting group description: Dose-Escalation: Participants received 0.8 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.	
Reporting group title	Phase I (Tablet) Cobimetinib (1 mg/kg)
Reporting group description: Dose-Escalation: Participants received 1 milligram per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.	
Reporting group title	Phase I (Suspension) Cobimetinib (0.6 mg/kg)
Reporting group description: Dose-Escalation: Participants received 0.6 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.	
Reporting group title	Phase I (Suspension) Cobimetinib (0.8 mg/kg)
Reporting group description: Dose-Escalation: Participants received 0.8 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.	
Reporting group title	Phase I (Suspension) Cobimetinib (1 mg/kg)
Reporting group description: Dose-Escalation: Participants received 1 milligram per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.	
Reporting group title	Phase I (Suspension) Cobimetinib (1.33 mg/kg)
Reporting group description: Dose-Escalation: Participants received 1.33 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.	
Reporting group title	Phase II (Suspension) Cobimetinib (1 mg/kg)
Reporting group description: Dose-Expansion: Participants received 1 milligram per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.	

<b>Reporting group values</b>	Phase I (Tablet) Cobimetinib (0.6 mg/kg)	Phase I (Tablet) Cobimetinib (0.8 mg/kg)	Phase I (Tablet) Cobimetinib (1 mg/kg)
Number of subjects	6	6	6
Age categorial Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	3	4	5
Adolescents (12-17 years)	3	2	1
Adults (18-64 years)	0	0	0
From 65-84 years	0	0	0
85 years and over	0	0	0

Age Continuous Units: Years arithmetic mean standard deviation	11.8 ± 3.5	9.5 ± 3.3	9.5 ± 3.4
Sex: Female, Male Units:			
Female	1	2	4
Male	5	4	2
Race/Ethnicity, Customized Units: Subjects			
Hispanic or Latino	1	1	0
Not Hispanic or Latino	5	3	4
Not Stated	0	2	2
Race/Ethnicity, Customized Units: Subjects			
Asian	0	0	0
Black or African American	0	1	1
Unknown	1	1	2
White	5	4	3
Tumor Type Units: Subjects			
Neuroblastoma	0	0	1
High-Grade Glioma	3	1	0
Low-Grade Glioma	1	2	4
Dnet In Noonan's Syndrome	0	0	0
Malignant Peripheral Nerve Sheath Tumor	0	0	0
Metastatic Mediastinal Yolk Sac Tumor	1	0	0
Non-Rhabdomyosarcoma Soft Tissue Sarcoma	0	1	0
Plexiform Neurofibroma	1	2	1
Rhabdoid Tumor/ATRT	0	0	0

<b>Reporting group values</b>	Phase I (Suspension) Cobimetinib (0.6 mg/kg)	Phase I (Suspension) Cobimetinib (0.8 mg/kg)	Phase I (Suspension) Cobimetinib (1 mg/kg)
Number of subjects	6	7	8
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	6	5	6
Adolescents (12-17 years)	0	2	2
Adults (18-64 years)	0	0	0
From 65-84 years	0	0	0
85 years and over	0	0	0

Age Continuous Units: Years arithmetic mean standard deviation	8.5 ± 1.4	9.7 ± 5.3	8.9 ± 3.1
Sex: Female, Male Units:			
Female	2	0	2
Male	4	7	6
Race/Ethnicity, Customized Units: Subjects			
Hispanic or Latino	1	2	1
Not Hispanic or Latino	1	2	4
Not Stated	4	3	3
Race/Ethnicity, Customized Units: Subjects			
Asian	0	1	0
Black or African American	1	0	0
Unknown	5	4	3
White	0	2	5
Tumor Type Units: Subjects			
Neuroblastoma	0	0	0
High-Grade Glioma	0	1	0
Low-Grade Glioma	5	3	2
Dnet In Noonan's Syndrome	0	0	0
Malignant Peripheral Nerve Sheath Tumor	0	1	1
Metastatic Mediastinal Yolk Sac Tumor	0	0	0
Non-Rhabdomyosarcoma Soft Tissue Sarcoma	0	0	0
Plexiform Neurofibroma	1	2	4
Rhabdoid Tumor/ATRT	0	0	1

<b>Reporting group values</b>	Phase I (Suspension) Cobimetinib (1.33 mg/kg)	Phase II (Suspension) Cobimetinib (1 mg/kg)	Total
Number of subjects	5	12	56
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	3	9	41
Adolescents (12-17 years)	2	2	14
Adults (18-64 years)	0	1	1
From 65-84 years	0	0	0
85 years and over	0	0	0

Age Continuous Units: Years arithmetic mean standard deviation	10.2 ± 3.3	8.7 ± 7.5	-
Sex: Female, Male Units:			
Female	5	7	23
Male	0	5	33
Race/Ethnicity, Customized Units: Subjects			
Hispanic or Latino	1	4	11
Not Hispanic or Latino	3	7	29
Not Stated	1	1	16
Race/Ethnicity, Customized Units: Subjects			
Asian	0	0	1
Black or African American	0	0	3
Unknown	1	1	18
White	4	11	34
Tumor Type Units: Subjects			
Neuroblastoma	0	0	1
High-Grade Glioma	0	0	5
Low-Grade Glioma	3	12	32
Dnet In Noonan's Syndrome	1	0	1
Malignant Peripheral Nerve Sheath Tumor	0	0	2
Metastatic Mediastinal Yolk Sac Tumor	0	0	1
Non-Rhabdomyosarcoma Soft Tissue Sarcoma	0	0	1
Plexiform Neurofibroma	1	0	12
Rhabdoid Tumor/ATRT	0	0	1

## End points

### End points reporting groups

Reporting group title	Phase I (Tablet) Cobimetinib (0.6 mg/kg)
Reporting group description: Dose-Escalation: Participants received 0.6 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.	
Reporting group title	Phase I (Tablet) Cobimetinib (0.8 mg/kg)
Reporting group description: Dose-Escalation: Participants received 0.8 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.	
Reporting group title	Phase I (Tablet) Cobimetinib (1 mg/kg)
Reporting group description: Dose-Escalation: Participants received 1 milligram per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.	
Reporting group title	Phase I (Suspension) Cobimetinib (0.6 mg/kg)
Reporting group description: Dose-Escalation: Participants received 0.6 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.	
Reporting group title	Phase I (Suspension) Cobimetinib (0.8 mg/kg)
Reporting group description: Dose-Escalation: Participants received 0.8 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.	
Reporting group title	Phase I (Suspension) Cobimetinib (1 mg/kg)
Reporting group description: Dose-Escalation: Participants received 1 milligram per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.	
Reporting group title	Phase I (Suspension) Cobimetinib (1.33 mg/kg)
Reporting group description: Dose-Escalation: Participants received 1.33 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.	
Reporting group title	Phase II (Suspension) Cobimetinib (1 mg/kg)
Reporting group description: Dose-Expansion: Participants received 1 milligram per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.	
Subject analysis set title	Cobimetinib (Tablet) Population
Subject analysis set type	Sub-group analysis
Subject analysis set description: Participants received Cobimetinib (Tablet) Formulation.	
Subject analysis set title	Cobimetinib (Suspension) Population
Subject analysis set type	Sub-group analysis
Subject analysis set description: Participants received Cobimetinib (Suspension) Formulation.	
Subject analysis set title	Neuroblastoma
Subject analysis set type	Sub-group analysis
Subject analysis set description: Participants with Neuroblastoma.	
Subject analysis set title	High Grade Glioma
Subject analysis set type	Sub-group analysis
Subject analysis set description: Participants with High Grade Glioma.	
Subject analysis set title	Low Grade Glioma (Phase I and II)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants with Low Grade Glioma.

Subject analysis set title	Dnet In Noonan's Syn Tumr (RAS/RAF/MEK/ERK Pathway Activation)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants with Dnet In Noonan's Syndrome Tumor With RAS/RAF/MEK/ERK Pathway Activation.

Subject analysis set title	Malignant Peripheral Nerve Sheath Tumor
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants with Malignant Peripheral Nerve Sheath Tumor.

Subject analysis set title	Metstic Mdstnl Ylksc Tumr (RAS/RAF/MEK/ERK Pathway Activation)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants with Metastatic Mediastinal Yolk Sac Tumor With RAS/RAF/MEK/ERK Pathway Activation.

Subject analysis set title	Non-Rhabdomyosarcoma Soft Tissue Sarcoma
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants with Non-Rhabdomyosarcoma Soft Tissue Sarcoma.

Subject analysis set title	Plexiform Neurofibroma
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants with Plexiform Neurofibroma.

Subject analysis set title	Rhabdoid Tumor/ATRT
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants with Rhabdoid Tumor/ATRT.

Subject analysis set title	Low Grade Glioma (Phase II)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants with Low Grade Glioma.

Subject analysis set title	Phase I (Tablet) Cobimetinib (0.6 mg/kg) (PK Population)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Dose-Escalation: Participants received 0.6 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.

Subject analysis set title	Phase I (Tablet) Cobimetinib (0.8 mg/kg) (PK Population)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Dose-Escalation: Participants received 0.8 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.

Subject analysis set title	Phase I (Tablet) Cobimetinib (1 mg/kg) (PK Population)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Dose-Escalation: Participants received 1 milligram per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.

Subject analysis set title	Phase I (Suspension) Cobimetinib (0.6 mg/kg) (PK Population)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Dose-Escalation: Participants received 0.6 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.

Subject analysis set title	Phase I (Suspension) Cobimetinib (0.8 mg/kg) (PK Population)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Dose-Escalation: Participants received 0.8 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.

Subject analysis set title	Phase I (Suspension) Cobimetinib (1 mg/kg) (PK Population)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Dose-Escalation: Participants received 1 milligram per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.

Subject analysis set title	Phase I (Suspension) Cobimetinib (1.33 mg/kg) (PK Population)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Dose-Escalation: Participants received 1.33 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.

Subject analysis set title	Phase II (Suspension) Cobimetinib (1 mg/kg) (PK Population)
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Dose-Expansion: Participants received 1 milligram per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.

### Primary: Percentage of Participants with Dose-Limiting Toxicities (DLTs)

End point title	Percentage of Participants with Dose-Limiting Toxicities
-----------------	----------------------------------------------------------

End point description:

Dose-Limiting Toxicities (DLTs) were defined as cobimetinib-related adverse events occurring within the first 28 days of each administration of cobimetinib.

End point type	Primary
----------------	---------

End point timeframe:

Baseline up until 30 days after the last dose of study drug (up to 5 years, 2 months)

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No Statistical Analyses provided as no formal hypothesis testing was planned for this study.

End point values	Phase I (Tablet) Cobimetinib (0.6 mg/kg)	Phase I (Tablet) Cobimetinib (0.8 mg/kg)	Phase I (Tablet) Cobimetinib (1 mg/kg)	Phase I (Suspension) Cobimetinib (0.6 mg/kg)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	6	6	6
Units: Percentage of Participants				
number (not applicable)	0	0	33.3	16.7

End point values	Phase I (Suspension) Cobimetinib (0.8 mg/kg)	Phase I (Suspension) Cobimetinib (1 mg/kg)	Phase I (Suspension) Cobimetinib (1.33 mg/kg)	Phase II (Suspension) Cobimetinib (1 mg/kg)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	8	5	12
Units: Percentage of Participants				
number (not applicable)	0	0	60.0	0

## Statistical analyses

No statistical analyses for this end point

### Primary: Percentage of Participants with Adverse Events (AEs), including Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)

End point title	Percentage of Participants with Adverse Events (AEs), including Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs) <sup>[2]</sup>
-----------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------

End point description:

An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as AEs.

End point type	Primary
----------------	---------

End point timeframe:

Baseline up until 30 days after the last dose of study drug (up to 5 years, 2 months)

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No Statistical Analyses provided as no formal hypothesis testing was planned for this study.

End point values	Phase I (Tablet) Cobimetinib (0.6 mg/kg)	Phase I (Tablet) Cobimetinib (0.8 mg/kg)	Phase I (Tablet) Cobimetinib (1 mg/kg)	Phase I (Suspension) Cobimetinib (0.6 mg/kg)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	6	6	6
Units: Percentage of Participants				
number (not applicable)				
AEs	100.0	100.0	100.0	100.0
SAEs	33.3	33.3	33.3	33.3
AESIs	33.3	33.3	33.3	50.0

End point values	Phase I (Suspension) Cobimetinib (0.8 mg/kg)	Phase I (Suspension) Cobimetinib (1 mg/kg)	Phase I (Suspension) Cobimetinib (1.33 mg/kg)	Phase II (Suspension) Cobimetinib (1 mg/kg)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	8	5	12
Units: Percentage of Participants				
number (not applicable)				
AEs	100.0	100.0	100.0	100.0
SAEs	14.3	25.0	40.0	41.7

AESIs	42.9	25.0	100.0	58.3
-------	------	------	-------	------

## Statistical analyses

No statistical analyses for this end point

### Primary: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of Cobimetinib

End point title	Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of Cobimetinib <sup>[3]</sup>
-----------------	-----------------------------------------------------------------------------------------------

End point description:

A prior dose level was defined as an MTD/MAD if at a certain dose level, there were greater than or equal to (>=) 2 out of 6 participants who had Dose Limiting Toxicities (DLTs).

End point type	Primary
----------------	---------

End point timeframe:

Cycle 1 Day 1 up to Cycle 1 Day 28 (cycle length=28 days)

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No Statistical Analyses provided as no formal hypothesis testing was planned for this study.

End point values	Cobimetinib (Tablet) Population	Cobimetinib (Suspension) Population		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	18	38		
Units: mg/kg				
number (not applicable)	0.8	1		

## Statistical analyses

No statistical analyses for this end point

### Primary: Percentage of Participants with Objective Response (CR or PR) as Determined by the Investigator using RANO criteria for Participants with High-Grade Glioma (HGG) (Phase I) and RECIST v1.1 for Participants with Low-Grade Glioma (LGG) (Phase I and II)

End point title	Percentage of Participants with Objective Response (CR or PR) as Determined by the Investigator using RANO criteria for Participants with High-Grade Glioma (HGG) (Phase I) and RECIST v1.1 for Participants with Low-Grade Glioma (LGG) (Phase I and II) <sup>[4]</sup>
-----------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

End point description:

Tumor assessment was performed using Response Assessment in Neuro-Oncology (RANO) criteria for participants with HGG and Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) for participants with LGG. While the data for LGG in the phase II cohort is presented separately in other parts of the record, it was also considered useful to combine the data for LGG from phase I and phase II, which was done here. The safety evaluable population was defined as all participants who received at least one dose of study drug. Participants enrolled into phase I (Dose-Escalation) cohorts independent of

their tumor type. For phase II, only one tumor type cohort was opened (LGG). As the same criteria were not used to assess response in all tumor types, the efficacy analyses were broken down by tumor type.

End point type	Primary
----------------	---------

End point timeframe:

Baseline up to disease progression or death due to any cause, whichever occurs first (up to 5 years, 2 months)

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No Statistical Analyses provided as no formal hypothesis testing was planned for this study.

End point values	High Grade Glioma	Low Grade Glioma (Phase I and II)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	5	32		
Units: Percentage of Participants				
number (not applicable)	0	9.4		

## Statistical analyses

No statistical analyses for this end point

### **Primary: Percentage of Participants with Objective Response (Complete Response (CR) or Partial Response (PR)) as Determined by the Investigator using modified International Neuroblastoma Response Criteria (mINRC) for Participants with Neuroblastoma (Phase I)**

End point title	Percentage of Participants with Objective Response (Complete Response (CR) or Partial Response (PR)) as Determined by the Investigator using modified International Neuroblastoma Response Criteria (mINRC) for Participants with Neuroblastoma (Phase I) <sup>[5]</sup>
-----------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

End point description:

Tumor assessment was performed using mINRC for Participants with Neuroblastoma. The safety evaluable population was defined as all participants who received at least one dose of study drug. Participants enrolled into phase I (Dose-Escalation) cohorts independent of their tumor type. As the same criteria were not used to assess response in all tumor types, the efficacy analyses were broken down by tumor type.

End point type	Primary
----------------	---------

End point timeframe:

Baseline up to disease progression or death due to any cause, whichever occurs first (up to 5 years, 2 months)

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No Statistical Analyses provided as no formal hypothesis testing was planned for this study.

<b>End point values</b>	Neuroblastoma			
Subject group type	Subject analysis set			
Number of subjects analysed	1			
Units: Percentage of Participants	0			

## Statistical analyses

No statistical analyses for this end point

### Primary: Percentage of Participants with Objective Response (CR or PR) as Determined by the Investigator using RECIST v1.1 criteria for Participants with All Other Tumours (Phase I)

End point title	Percentage of Participants with Objective Response (CR or PR) as Determined by the Investigator using RECIST v1.1 criteria for Participants with All Other Tumours (Phase I) <sup>[6]</sup>
-----------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

End point description:

Tumor assessment was performed using RECIST v1.1 for Participants with All Other Tumours. The safety evaluable population was defined as all participants who received at least one dose of study drug. Participants enrolled into phase I (Dose-Escalation) cohorts independent of their tumor type. As the same criteria were not used to assess response in all tumor types, the efficacy analyses were broken down by tumor type.

End point type	Primary
----------------	---------

End point timeframe:

Baseline up to disease progression or death due to any cause, whichever occurs first (up to 5 years, 2 months)

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No Statistical Analyses provided as no formal hypothesis testing was planned for this study.

<b>End point values</b>	Dnet In Noonan's Syn Tumr (RAS/RAF/MEK /ERK Pathway Activation)	Malignant Peripheral Nerve Sheath Tumor	Metstic Mdstnl Ylksc Tumr (RAS/RAF/MEK /ERK Pathway Activation)	Non-Rhabdomyosarcoma Soft Tissue Sarcoma
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	1	2	1	1
Units: Percentage of Participants	0	0	0	0

<b>End point values</b>	Plexiform Neurofibroma	Rhabdoid Tumor/ATRT		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	12	1		
Units: Percentage of Participants	0	0		

## Statistical analyses

No statistical analyses for this end point

---

**Primary: Percentage of Participants with Objective Response (CR or PR) as Determined by the Investigator using RANO criteria for Participants with LGG (Phase II)**

---

End point title	Percentage of Participants with Objective Response (CR or PR) as Determined by the Investigator using RANO criteria for Participants with LGG (Phase II) <sup>[7]</sup>
-----------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------

End point description:

Tumor assessment was performed using RANO criteria for LGG. The safety evaluable population was defined as all participants who received at least one dose of study drug. For phase II, only one tumor type cohort was opened (LGG).

End point type	Primary
----------------	---------

End point timeframe:

Baseline up to disease progression or death due to any cause, whichever occurs first (up to 5 years, 2 months)

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No Statistical Analyses provided as no formal hypothesis testing was planned for this study.

End point values	Low Grade Glioma (Phase II)			
Subject group type	Subject analysis set			
Number of subjects analysed	12			
Units: Percentage of Participants				
number (not applicable)	8.3			

---

**Statistical analyses**

---

No statistical analyses for this end point

---

**Primary: Progression-Free Survival (PFS) as Determined by the Investigator using mINRC for Participants with Neuroblastoma (Phase I)**

---

End point title	Progression-Free Survival (PFS) as Determined by the Investigator using mINRC for Participants with Neuroblastoma (Phase I) <sup>[8]</sup>
-----------------	--------------------------------------------------------------------------------------------------------------------------------------------

End point description:

Tumor assessment was performed using mINRC for Participants with Neuroblastoma. The safety evaluable population was defined as all participants who received at least one dose of study drug. Participants enrolled into phase I (Dose-Escalation) cohorts independent of their tumor type. As the same criteria were not used to assess response in all tumor types, the efficacy analyses were broken down by tumor type.

0.0 to 9999999 = The confidence interval could not be calculated from the data of one participant.

End point type	Primary
----------------	---------

End point timeframe:

From the time of cobimetinib study drug initiation to the first documented disease progression, or death due to any cause, whichever occurs first (up to 5 years, 2 months)

Notes:

[8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No Statistical Analyses provided as no formal hypothesis testing was planned for this study.

<b>End point values</b>	Neuroblastoma			
Subject group type	Subject analysis set			
Number of subjects analysed	1			
Units: Months				
median (confidence interval 95%)	1.3 (0.0 to 9999999)			

## Statistical analyses

No statistical analyses for this end point

### Primary: PFS as Determined by the Investigator using RANO criteria for participants with HGG (Phase I) and RECIST v1.1 for participants with LGG (Phase I and II)

End point title	PFS as Determined by the Investigator using RANO criteria for participants with HGG (Phase I) and RECIST v1.1 for participants with LGG (Phase I and II) <sup>[9]</sup>
-----------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------

End point description:

Tumor assessment was performed using RANO for participants with HGG and RECIST v1.1 for participants with LGG. While the data for LGG in the phase II cohort is presented separately in other parts of the record, it was also considered useful to combine the data for LGG from phase I and phase II, which was done here. The safety evaluable population was defined as all participants who received at least one dose of study drug. Participants enrolled into phase I (Dose-Escalation) cohorts independent of their tumor type. For phase II, only one tumor type cohort was opened (LGG). As the same criteria were not used to assess response in all tumor types, the efficacy analyses were broken down by tumor type. 9999999 = The upper limit could not be calculated from the data due to insufficient number of participants with events.

End point type	Primary
----------------	---------

End point timeframe:

From the time of cobimetinib study drug initiation to the first documented disease progression, or death due to any cause, whichever occurs first (up to approximately 6.75 years)

Notes:

[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No Statistical Analyses provided as no formal hypothesis testing was planned for this study.

<b>End point values</b>	High Grade Glioma	Low Grade Glioma (Phase I and II)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	5	32		
Units: Months				
median (confidence interval 95%)	1.0 (0.6 to 9999999)	22.0 (9.3 to 9999999)		

## Statistical analyses

No statistical analyses for this end point

### Primary: PFS as Determined by the Investigator using RECIST v1.1 criteria for Participants with All Other Tumours (Phase I)

End point title	PFS as Determined by the Investigator using RECIST v1.1
-----------------	---------------------------------------------------------

End point description:

Tumor assessment was performed using RECIST v1.1 for Participants with All Other Tumours. The safety evaluable population was defined as all participants who received at least one dose of study drug. Participants enrolled into phase I (Dose-Escalation) cohorts independent of their tumor type. As the same criteria were not used to assess response in all tumor types, the efficacy analyses were broken down by tumor type.

9999999 = The median, upper and lower limits could not be calculated from the data due to insufficient number of participants with events.

End point type Primary

End point timeframe:

From the time of cobimetinib study drug initiation to the first documented disease progression, or death due to any cause, whichever occurs first (up to 5 years, 2 months)

Notes:

[10] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No Statistical Analyses provided as no formal hypothesis testing was planned for this study.

End point values	Dnet In Noonan's Syn Tumr (RAS/RAF/MEK/ERK Pathway Activation)	Malignant Peripheral Nerve Sheath Tumor	Metstic Mdstnl Ylksc Tumr (RAS/RAF/MEK/ERK Pathway Activation)	Non-Rhabdomyosarcoma Soft Tissue Sarcoma
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	1	2	1	1
Units: Months				
median (confidence interval 95%)	9999999 (0.0 to 9999999)	4.1 (0.7 to 9999999)	1.1 (0.0 to 9999999)	3.4 (0.0 to 9999999)

End point values	Plexiform Neurofibroma	Rhabdoid Tumor/ATRT		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	12	1		
Units: Months				
median (confidence interval 95%)	9999999 (18.4 to 9999999)	0.5 (0.0 to 9999999)		

**Statistical analyses**

No statistical analyses for this end point

**Primary: PFS as Determined by the Investigator using RANO criteria for Participants with LGG (Phase II)**

End point title PFS as Determined by the Investigator using RANO criteria for Participants with LGG (Phase II)<sup>[11]</sup>

End point description:

Tumor assessment was performed using RANO criteria for Participants with LGG. The safety evaluable population was defined as all participants who received at least one dose of study drug. For phase II, only one tumor type cohort was opened (LGG).

9999999 = The upper limit could not be calculated from the data due to insufficient number of participants with events.

End point type	Primary
----------------	---------

End point timeframe:

From the time of cobimetinib study drug initiation to the first documented disease progression, or death due to any cause, whichever occurs first (up to 5 years, 2 months)

Notes:

[11] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No Statistical Analyses provided as no formal hypothesis testing was planned for this study.

<b>End point values</b>	Low Grade Glioma (Phase II)			
Subject group type	Subject analysis set			
Number of subjects analysed	12			
Units: Months				
median (confidence interval 95%)	18.4 (3.6 to 9999999)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Duration of Response (DOR) as Determined by the Investigator using RECIST v1.1 for participants with LGG (Phase I and II)

End point title	Duration of Response (DOR) as Determined by the Investigator using RECIST v1.1 for participants with LGG (Phase I and II)
-----------------	---------------------------------------------------------------------------------------------------------------------------

End point description:

Tumor assessment was performed using RECIST v1.1 criteria for participants with LGG. While the data for LGG in the phase II cohort is presented separately in other parts of the record, it was also considered useful to combine the data for LGG from phase I and phase II, which was done here. The safety evaluable population was defined as all participants who received at least one dose of study drug. Participants enrolled into phase I (Dose-Escalation) cohorts independent of their tumor type. For phase II, only one tumor type cohort was opened (LGG). As the same criteria were not used to assess response in all tumor types, the efficacy analyses were broken down by tumor type. 9999999, 0.0 to 9999999 = no participants experienced an event and DOR wasn't reached.

End point type	Secondary
----------------	-----------

End point timeframe:

From first occurrence of objective response to disease progression or death due to any cause, whichever occurs first (up to 5 years, 2 months)

<b>End point values</b>	Low Grade Glioma (Phase I and II)			
Subject group type	Subject analysis set			
Number of subjects analysed	3			
Units: Months				
median (confidence interval 95%)	9999999 (0.0 to 9999999)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Recommended Phase II Dose (RP2D) of Cobimetinib

End point title Recommended Phase II Dose (RP2D) of Cobimetinib

End point description:

A prior dose level was defined as an RP2D if at a certain dose level, there were greater than or equal to ( $\geq$ ) 2 out of 6 participants who had Dose Limiting Toxicities (DLTs).

End point type Secondary

End point timeframe:

Cycle 1 Day 1 up to Cycle 1 Day 28 (cycle length=28 days)

End point values	Cobimetinib (Suspension) Population			
Subject group type	Subject analysis set			
Number of subjects analysed	38			
Units: mg/kg	1			

## Statistical analyses

No statistical analyses for this end point

### Secondary: DOR as Determined by the Investigator RANO criteria for Participants with LGG (Phase II)

End point title DOR as Determined by the Investigator RANO criteria for Participants with LGG (Phase II)

End point description:

Tumor assessment was performed using RANO criteria for Participants with LGG. The safety evaluable population was defined as all participants who received at least one dose of study drug. For phase II, only one tumor type cohort was opened (LGG).

9999999, 0.0 to 9999999 = no participants experienced an event and DOR wasn't reached.

End point type Secondary

End point timeframe:

From first occurrence of objective response to disease progression or death due to any cause, whichever occurs first (up to 5 years, 2 months)

End point values	Low Grade Glioma (Phase II)			
Subject group type	Subject analysis set			
Number of subjects analysed	1			
Units: Months				
median (confidence interval 95%)	9999999 (0.0 to 9999999)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Overall Survival (OS) for Participants with Neuroblastoma (Phase I)

End point title	Overall Survival (OS) for Participants with Neuroblastoma (Phase I)
-----------------	---------------------------------------------------------------------

End point description:

OS was defined as the time from initiation of study drug to death from any cause. The safety evaluable population was defined as all participants who received at least one dose of study drug. Participants enrolled into phase I (Dose-Escalation) cohorts independent of their tumor type. As the same criteria were not used to assess response in all tumor types, the efficacy analyses were broken down by tumor type.

0.0 to 9999999 = The 95% confidence interval could not be calculated from the data of one participant.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline until death due to any cause (up to 5 years, 2 months)

End point values	Neuroblastoma			
Subject group type	Subject analysis set			
Number of subjects analysed	1			
Units: Months				
median (confidence interval 95%)	4.6 (0.0 to 9999999)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: OS for Participants with High-Grade Glioma (HGG) (Phase I) and Low-Grade Glioma (LGG) (Phase I and II)

End point title	OS for Participants with High-Grade Glioma (HGG) (Phase I) and Low-Grade Glioma (LGG) (Phase I and II)
-----------------	--------------------------------------------------------------------------------------------------------

End point description:

OS was defined as the time from initiation of study drug to death from any cause. While the data for LGG in the phase II cohort is presented separately in other parts of the record, it was also considered useful to combine the data for LGG from phase I and phase II, which was done here. The safety evaluable population was defined as all participants who received at least one dose of study drug. Participants enrolled into phase I (Dose-Escalation) cohorts independent of their tumor type. For phase II, only one tumor type cohort was opened (LGG). As the same criteria were not used to assess response in all tumor types, the efficacy analyses were broken down by tumor type.

9999999 = The upper limit cannot be calculated due to insufficient number of events. (HGG)

9999999, 0.0 to 9999999 = No participants experienced an event and DOR was not reached (LGG)

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline until death due to any cause (up to 5 years, 2 months)

<b>End point values</b>	High Grade Glioma	Low Grade Glioma (Phase I and II)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	5	32		
Units: Months				
median (confidence interval 95%)	1.4 (0.6 to 9999999)	9999999 (0.0 to 9999999)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: OS for Participants with All Other Tumours (Phase I)

End point title OS for Participants with All Other Tumours (Phase I)

End point description:

OS was defined as the time from initiation of study drug to death from any cause. The safety evaluable population was defined as all participants who received at least one dose of study drug. Participants enrolled into phase I (Dose-Escalation) cohorts independent of their tumor type. As the same criteria were not used to assess response in all tumor types, the efficacy analyses were broken down by tumor type.

9999999 = The median and 95% confidence interval could not be calculated from the data due to insufficient number of participants with events.

End point type Secondary

End point timeframe:

Baseline until death due to any cause (up to 5 years, 2 months)

<b>End point values</b>	Dnet In Noonan's Syn Tumr (RAS/RAF/MEK /ERK Pathway Activation)	Malignant Peripheral Nerve Sheath Tumor	Metstic Mdstnl Ylksc Tumr (RAS/RAF/MEK /ERK Pathway Activation)	Non-Rhabdomyosarcoma Soft Tissue Sarcoma
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	1	2	1	1
Units: Months				
median (confidence interval 95%)	9999999 (0.0 to 9999999)	5.5 (0.8 to 9999999)	1.1 (0.0 to 9999999)	6.3 (0.0 to 9999999)

<b>End point values</b>	Plexiform Neurofibroma	Rhabdoid Tumor/ATRT		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	12	1		

Units: Months				
median (confidence interval 95%)	9999999 (0.0 to 9999999)	5.1 (0.0 to 9999999)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Maximum Plasma Concentration Observed (Cmax) of Cobimetinib

End point title	Maximum Plasma Concentration Observed (Cmax) of Cobimetinib
End point description:	Plasma samples for determination of Cobimetinib concentration were collected prior to dosing and at 2, 4, 6 and 24 hours after dosing on Days 1 and 21 of Cycle 1. The sampling will allow determination of Cmax.
End point type	Secondary
End point timeframe:	Pre-dose, 2, 4, 6, and 24 hours post-dose on Cycle 1 Days 1 and 21 (predose=within 4 hours prior to dose; cycle length=28 days)

End point values	Phase I (Tablet) Cobimetinib (0.6 mg/kg) (PK Population)	Phase I (Tablet) Cobimetinib (0.8 mg/kg) (PK Population)	Phase I (Tablet) Cobimetinib (1 mg/kg) (PK Population)	Phase I (Suspension) Cobimetinib (0.6 mg/kg) (PK Population)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	6	6	6	6
Units: ng/mL				
geometric mean (geometric coefficient of variation)				
Cycle 1 Day 1 (n= 6,5,6,6,7,8,4,9)	62.0 (± 82.3)	88.3 (± 102)	144 (± 58.6)	51.5 (± 73.4)
Cycle 1 Day 21 (n= 5,5,6,6,7,8,4,9)	51.1 (± 74.0)	181 (± 134)	193 (± 35.0)	105 (± 84.5)

End point values	Phase I (Suspension) Cobimetinib (0.8 mg/kg) (PK Population)	Phase I (Suspension) Cobimetinib (1 mg/kg) (PK Population)	Phase I (Suspension) Cobimetinib (1.33 mg/kg) (PK Population)	Phase II (Suspension) Cobimetinib (1 mg/kg) (PK Population)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	7	8	5	12
Units: ng/mL				
geometric mean (geometric coefficient of variation)				
Cycle 1 Day 1 (n= 6,5,6,6,7,8,4,9)	67.4 (± 165)	136 (± 80.3)	111 (± 37.0)	44.0 (± 69.8)
Cycle 1 Day 21 (n= 5,5,6,6,7,8,4,9)	156 (± 91.2)	179 (± 113)	172 (± 60.3)	116 (± 42)

## Statistical analyses

No statistical analyses for this end point

### Secondary: Time to Cmax (Tmax) of Cobimetinib

End point title	Time to Cmax (Tmax) of Cobimetinib
-----------------	------------------------------------

End point description:

Plasma samples for determination of Cobimetinib concentration will be collected prior to dosing and at 2, 4, 6 and 24 hours after dosing on Days 1 and 21 of Cycle 1. The sampling will allow determination of Tmax.

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-dose, 2, 4, 6, and 24 hours post-dose on Cycle 1 Days 1 and 21 (pre-dose=within 4 hours prior to dose; cycle length=28 days)

End point values	Phase I (Tablet) Cobimetinib (0.6 mg/kg) (PK Population)	Phase I (Tablet) Cobimetinib (0.8 mg/kg) (PK Population)	Phase I (Tablet) Cobimetinib (1 mg/kg) (PK Population)	Phase I (Suspension) Cobimetinib (0.6 mg/kg) (PK Population)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	6	6	6	6
Units: hr				
median (full range (min-max))				
Cycle 1 Day 1 (n= 6,5,6,6,7,8,4,9)	4 (2 to 6)	2 (2 to 6)	3 (2 to 4)	4 (2 to 6)
Cycle 1 Day 21 (n= 5,5,5,6,6,8,2,9)	4 (2 to 6)	4 (2 to 6)	2 (2 to 4)	4 (2 to 6)

End point values	Phase I (Suspension) Cobimetinib (0.8 mg/kg) (PK Population)	Phase I (Suspension) Cobimetinib (1 mg/kg) (PK Population)	Phase I (Suspension) Cobimetinib (1.33 mg/kg) (PK Population)	Phase II (Suspension) Cobimetinib (1 mg/kg) (PK Population)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	7	8	5	12
Units: hr				
median (full range (min-max))				
Cycle 1 Day 1 (n= 6,5,6,6,7,8,4,9)	4 (2 to 6)	2 (2 to 4)	5 (2 to 6)	4 (2 to 6)
Cycle 1 Day 21 (n= 5,5,5,6,6,8,2,9)	2 (2 to 4)	3 (2 to 6)	4 (4 to 4)	2 (2 to 6)

## Statistical analyses

No statistical analyses for this end point

### Secondary: Area Under the Concentration-Time Curve From 0 to 24 Hours (AUC0-24) of Cobimetinib

End point title	Area Under the Concentration-Time Curve From 0 to 24 Hours (AUC0-24) of Cobimetinib
-----------------	-------------------------------------------------------------------------------------

End point description:

Plasma samples for determination of Cobimetinib concentration were collected prior to dosing and at 2, 4, 6 and 24 hours after dosing on Days 1 and 21 of Cycle 1. The sampling will allow determination of AUC0-24.

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-dose, 2, 4, 6, and 24 hours post-dose on Cycle 1 Days 1 and 21 (pre-dose=within 4 hours prior to dose; cycle length=28 days)

End point values	Phase I (Tablet) Cobimetinib (0.6 mg/kg) (PK Population)	Phase I (Tablet) Cobimetinib (0.8 mg/kg) (PK Population)	Phase I (Tablet) Cobimetinib (1 mg/kg) (PK Population)	Phase I (Suspension) Cobimetinib (0.6 mg/kg) (PK Population)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	6	6	6	6
Units: hr*ng/mL				
geometric mean (geometric coefficient of variation)				
Cycle 1 Day 1 (n= 6,5,6,6,6,8,3,9)	865 (± 83.0)	1006 (± 100)	1432 (± 50.0)	743 (± 67.4)
Cycle 1 Day 21 (n= 5,5,5,6,6,8,2,9)	836 (± 83.5)	2802 (± 111)	2382 (± 38.4)	1624 (± 80.4)

End point values	Phase I (Suspension) Cobimetinib (0.8 mg/kg) (PK Population)	Phase I (Suspension) Cobimetinib (1 mg/kg) (PK Population)	Phase I (Suspension) Cobimetinib (1.33 mg/kg) (PK Population)	Phase II (Suspension) Cobimetinib (1 mg/kg) (PK Population)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	7	8	5	12
Units: hr*ng/mL				
geometric mean (geometric coefficient of variation)				
Cycle 1 Day 1 (n= 6,5,6,6,6,8,3,9)	1111 (± 144)	1627 (± 74.0)	1567 (± 33.1)	589 (± 79.5)
Cycle 1 Day 21 (n= 5,5,5,6,6,8,2,9)	1805 (± 109)	2562 (± 104)	2511 (± 104)	1402 (± 59)

### Statistical analyses

No statistical analyses for this end point

### Secondary: Apparent Clearance (CL/F) of Cobimetinib

End point title	Apparent Clearance (CL/F) of Cobimetinib
-----------------	------------------------------------------

**End point description:**

Plasma samples for determination of Cobimetinib concentration were collected prior to dosing and at 2, 4, 6 and 24 hours after dosing on Days 1 and 21 of Cycle 1, and within 4 hours prior to dosing on Day 1 of Cycle 2. Please note that for this Outcome Measure, the Apparent Clearance of Cobimetinib could not be calculated/estimated as PK samples were collected only up to 24hr post dosing.

9999999 = The Apparent Clearance of Cobimetinib could not be calculated/estimated as PK samples were collected only up to 24hr post dosing which resulted in insufficient data to calculate CL/F.

End point type	Secondary
----------------	-----------

**End point timeframe:**

Pre-dose, 2, 4, 6, and 24 hours post-dose on Cycle 1 Days 1 and 21; pre-dose on Cycle 2 Day 1 (pre-dose=within 4 hours prior to dose; cycle length=28 days)

<b>End point values</b>	Phase I (Tablet) Cobimetinib (0.6 mg/kg) (PK Population)	Phase I (Tablet) Cobimetinib (0.8 mg/kg) (PK Population)	Phase I (Tablet) Cobimetinib (1 mg/kg) (PK Population)	Phase I (Suspension) Cobimetinib (0.6 mg/kg) (PK Population)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	6	6	6	6
Units: L/hr				
geometric mean (geometric coefficient of variation)	9999999 (± 9999999)	9999999 (± 9999999)	9999999 (± 9999999)	9999999 (± 9999999)

<b>End point values</b>	Phase I (Suspension) Cobimetinib (0.8 mg/kg) (PK Population)	Phase I (Suspension) Cobimetinib (1 mg/kg) (PK Population)	Phase I (Suspension) Cobimetinib (1.33 mg/kg) (PK Population)	Phase II (Suspension) Cobimetinib (1 mg/kg) (PK Population)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	7	8	5	12
Units: L/hr				
geometric mean (geometric coefficient of variation)	9999999 (± 9999999)	9999999 (± 9999999)	9999999 (± 9999999)	9999999 (± 9999999)

**Statistical analyses**

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Baseline up until 30 days after the last dose of study drug (up to 5 years, 2 months)

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	24.0
--------------------	------

### Reporting groups

Reporting group title	Phase I (Tablet) Cobimetinib (0.6 mg/kg)
-----------------------	------------------------------------------

Reporting group description:

Dose-Escalation: Participants received 0.6 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.

Reporting group title	Phase I (Tablet) Cobimetinib (0.8 mg/kg)
-----------------------	------------------------------------------

Reporting group description:

Dose-Escalation: Participants received 0.8 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.

Reporting group title	Phase I (Tablet) Cobimetinib (1 mg/kg)
-----------------------	----------------------------------------

Reporting group description:

Dose-Escalation: Participants received 1 milligram per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.

Reporting group title	Phase I (Suspension) Cobimetinib (0.6 mg/kg)
-----------------------	----------------------------------------------

Reporting group description:

Dose-Escalation: Participants received 0.6 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.

Reporting group title	Phase I (Suspension) Cobimetinib (1 mg/kg)
-----------------------	--------------------------------------------

Reporting group description:

Dose-Escalation: Participants received 1 milligram per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.

Reporting group title	Phase I (Suspension) Cobimetinib (0.8 mg/kg)
-----------------------	----------------------------------------------

Reporting group description:

Dose-Escalation: Participants received 0.8 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.

Reporting group title	Phase I (Suspension) Cobimetinib (1.33 mg/kg)
-----------------------	-----------------------------------------------

Reporting group description:

Dose-Escalation: Participants received 1.33 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.

Reporting group title	Phase II (Suspension) Cobimetinib (1 mg/kg)
-----------------------	---------------------------------------------

Reporting group description:

Dose-Expansion: Participants received 1 milligram per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.

<b>Serious adverse events</b>	Phase I (Tablet) Cobimetinib (0.6 mg/kg)	Phase I (Tablet) Cobimetinib (0.8 mg/kg)	Phase I (Tablet) Cobimetinib (1 mg/kg)
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 6 (33.33%)	2 / 6 (33.33%)	2 / 6 (33.33%)
number of deaths (all causes)	2	2	1
number of deaths resulting from	0	0	0

adverse events			
<b>Investigations</b>			
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Injury, poisoning and procedural complications</b>			
Femoral neck fracture			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Cardiac disorders</b>			
Cardiac ventricular thrombosis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericardial effusion			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Nervous system disorders</b>			
Headache			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Somnolence			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydrocephalus			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalopathy			

subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Seizure</b>			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Neuralgia</b>			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>General disorders and administration site conditions</b>			
<b>Pyrexia</b>			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Eye disorders</b>			
<b>Chorioretinopathy</b>			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Gastrointestinal disorders</b>			
<b>Vomiting</b>			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Abdominal pain</b>			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Respiratory, thoracic and mediastinal disorders</b>			
<b>Pneumothorax</b>			

subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Musculoskeletal and connective tissue disorders</b>			
Pain in extremity			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Infections and infestations</b>			
Infection			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Paronychia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular device infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Catheter site infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Phase I (Suspension) Cobimetinib (0.6 mg/kg)	Phase I (Suspension) Cobimetinib (1 mg/kg)	Phase I (Suspension) Cobimetinib (0.8 mg/kg)
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 6 (33.33%)	2 / 8 (25.00%)	1 / 7 (14.29%)
number of deaths (all causes)	2	2	2
number of deaths resulting from adverse events	0	0	0
Investigations			
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Femoral neck fracture			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Cardiac ventricular thrombosis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	1 / 7 (14.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericardial effusion			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			

Headache			
subjects affected / exposed	1 / 6 (16.67%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Somnolence			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydrocephalus			
subjects affected / exposed	1 / 6 (16.67%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalopathy			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neuralgia			
subjects affected / exposed	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Chorioretinopathy			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Gastrointestinal disorders			
Vomiting			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain			
subjects affected / exposed	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Pneumothorax			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Pain in extremity			
subjects affected / exposed	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Paronychia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			

subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Gastroenteritis</b>			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Vascular device infection</b>			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Catheter site infection</b>			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Skin infection</b>			
subjects affected / exposed	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Phase I (Suspension) Cobimetinib (1.33 mg/kg)	Phase II (Suspension) Cobimetinib (1 mg/kg)	
<b>Total subjects affected by serious adverse events</b>			
subjects affected / exposed	2 / 5 (40.00%)	5 / 12 (41.67%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
<b>Investigations</b>			
<b>Blood creatine phosphokinase increased</b>			
subjects affected / exposed	0 / 5 (0.00%)	1 / 12 (8.33%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Injury, poisoning and procedural complications</b>			
Femoral neck fracture			

subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Cardiac disorders</b>			
Cardiac ventricular thrombosis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericardial effusion			
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Nervous system disorders</b>			
Headache			
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Somnolence			
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydrocephalus			
subjects affected / exposed	0 / 5 (0.00%)	1 / 12 (8.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Encephalopathy			
subjects affected / exposed	0 / 5 (0.00%)	1 / 12 (8.33%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Seizure			
subjects affected / exposed	0 / 5 (0.00%)	1 / 12 (8.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuralgia			

subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>General disorders and administration site conditions</b>			
Pyrexia			
subjects affected / exposed	1 / 5 (20.00%)	0 / 12 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Eye disorders</b>			
Chorioretinopathy			
subjects affected / exposed	1 / 5 (20.00%)	0 / 12 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Gastrointestinal disorders</b>			
Vomiting			
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Respiratory, thoracic and mediastinal disorders</b>			
Pneumothorax			
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Musculoskeletal and connective tissue disorders</b>			
Pain in extremity			
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Infections and infestations</b>			

Infection			
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paronychia			
subjects affected / exposed	1 / 5 (20.00%)	0 / 12 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper respiratory tract infection			
subjects affected / exposed	0 / 5 (0.00%)	1 / 12 (8.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis			
subjects affected / exposed	0 / 5 (0.00%)	1 / 12 (8.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular device infection			
subjects affected / exposed	1 / 5 (20.00%)	0 / 12 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Catheter site infection			
subjects affected / exposed	1 / 5 (20.00%)	0 / 12 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin infection			
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Phase I (Tablet) Cobimetinib (0.6 mg/kg)	Phase I (Tablet) Cobimetinib (0.8 mg/kg)	Phase I (Tablet) Cobimetinib (1 mg/kg)
Total subjects affected by non-serious adverse events subjects affected / exposed	6 / 6 (100.00%)	6 / 6 (100.00%)	6 / 6 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Skin papilloma subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 6 (16.67%) 1	0 / 6 (0.00%) 0
Hair follicle tumour benign subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Vascular disorders Hypertension subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
General disorders and administration site conditions Gait disturbance subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Chest pain subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 6 (16.67%) 1	0 / 6 (0.00%) 0
Fatigue subjects affected / exposed occurrences (all)	2 / 6 (33.33%) 2	2 / 6 (33.33%) 2	3 / 6 (50.00%) 5
Inflammation subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Localised oedema subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Oedema peripheral subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0

Xerosis			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Nodule			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Asthenia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Mucosal inflammation			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Extravasation			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Malaise			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	2 / 6 (33.33%)	1 / 6 (16.67%)	1 / 6 (16.67%)
occurrences (all)	2	2	3
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Reproductive system and breast disorders			
Balanoposthitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Scrotal ulcer			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Vulvovaginal pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			

Epistaxis			
subjects affected / exposed	1 / 6 (16.67%)	1 / 6 (16.67%)	1 / 6 (16.67%)
occurrences (all)	3	1	2
Dyspnoea			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	3	0	0
Nasal congestion			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences (all)	0	2	0
Pleural effusion			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Oropharyngeal pain			
subjects affected / exposed	1 / 6 (16.67%)	1 / 6 (16.67%)	1 / 6 (16.67%)
occurrences (all)	1	1	2
Rhinorrhoea			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	1	0	1
Pneumonia aspiration			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Cough			
subjects affected / exposed	2 / 6 (33.33%)	2 / 6 (33.33%)	1 / 6 (16.67%)
occurrences (all)	3	4	1
Sputum decreased			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Psychiatric disorders			
Insomnia			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	1	0	1
Behaviour disorder			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Anxiety			

subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	2
Inappropriate affect			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Bradypnea			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Investigations			
Blood bicarbonate decreased			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Ejection fraction decreased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blood chloride increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Aspartate aminotransferase increased			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
White blood cell count decreased			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences (all)	0	9	0
Blood creatinine decreased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Anion gap increased			

subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Lymphocyte count decreased subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Weight decreased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Body temperature decreased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 6 (16.67%) 1	0 / 6 (0.00%) 0
Platelet count increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Cortisol decreased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	1 / 6 (16.67%) 1
Intraocular pressure increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	1 / 6 (16.67%) 1
Neutrophil count decreased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 6 (16.67%) 7	0 / 6 (0.00%) 0
Transaminases increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Gamma-glutamyltransferase increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 6 (16.67%) 1	0 / 6 (0.00%) 0
Protein total decreased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Blood creatinine increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	1 / 6 (16.67%) 1

Mean cell volume increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Lymphocyte count increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Blood creatine phosphokinase increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	1 / 6 (16.67%) 3
White blood cell count increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Body temperature increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	1 / 6 (16.67%) 1
Oxygen saturation decreased subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Weight increased subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Blood cholesterol increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Platelet count decreased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Neutrophil count increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Injury, poisoning and procedural complications			

Skin abrasion			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	1 / 6 (16.67%)
occurrences (all)	0	1	2
Face injury			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Thermal burn			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Wrist fracture			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Foreign body in ear			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Hand fracture			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Contusion			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	3
Limb injury			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	3
Arthropod bite			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Ligament sprain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Foot fracture			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Head injury			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	5

Skin laceration subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Tooth fracture subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	1 / 6 (16.67%) 1
Fall subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	1 / 6 (16.67%) 4
Abdominal injury subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	1 / 6 (16.67%) 1
Skin wound subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Congenital, familial and genetic disorders Iris hamartoma subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	1 / 6 (16.67%) 1
Cardiac disorders Sinus tachycardia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Nervous system disorders Headache subjects affected / exposed occurrences (all)	3 / 6 (50.00%) 5	3 / 6 (50.00%) 4	2 / 6 (33.33%) 2
Dizziness subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 6 (0.00%) 0	1 / 6 (16.67%) 2
Paraesthesia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 6 (16.67%) 1	1 / 6 (16.67%) 4
Tremor subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0

Lethargy			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Sciatica			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Neuralgia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Thrombocytopenia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Leukopenia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Anaemia			
subjects affected / exposed	0 / 6 (0.00%)	2 / 6 (33.33%)	0 / 6 (0.00%)
occurrences (all)	0	7	0
Lymphadenopathy			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Ear and labyrinth disorders			
Ear pain			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	1 / 6 (16.67%)
occurrences (all)	0	1	1
Eye disorders			
Retinal detachment			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Vision blurred			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis allergic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Ocular hyperaemia			

subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
Punctate keratitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Ocular hypertension			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Miosis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Detachment of retinal pigment epithelium			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Optic disc disorder			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Visual acuity reduced transiently			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Serous retinal detachment			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Retinal disorder			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Corneal neovascularisation			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Optic atrophy			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dry eye			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0

Visual impairment			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Eye pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Eye disorder			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Visual field defect			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Eyelid skin dryness			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Eyelid ptosis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Chorioretinopathy			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Toothache			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dyspepsia			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Tongue ulceration			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	2
Abdominal pain upper			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	1 / 6 (16.67%)
occurrences (all)	0	1	1
Lip haemorrhage			

subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Vomiting			
subjects affected / exposed	1 / 6 (16.67%)	2 / 6 (33.33%)	4 / 6 (66.67%)
occurrences (all)	1	4	9
Anal haemorrhage			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Constipation			
subjects affected / exposed	3 / 6 (50.00%)	2 / 6 (33.33%)	3 / 6 (50.00%)
occurrences (all)	3	3	5
Lip ulceration			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dysphagia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Glossodynia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	2
Oesophagitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Haematochezia			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Proctalgia			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Dry mouth			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Nausea			
subjects affected / exposed	2 / 6 (33.33%)	1 / 6 (16.67%)	3 / 6 (50.00%)
occurrences (all)	2	1	3
Gastrooesophageal reflux disease			

subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	1	0	1
Gastritis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dental caries			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Abdominal distension			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Stomatitis			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
Faeces hard			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Tooth impacted			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Abdominal pain			
subjects affected / exposed	2 / 6 (33.33%)	3 / 6 (50.00%)	2 / 6 (33.33%)
occurrences (all)	2	3	2
Diarrhoea			
subjects affected / exposed	3 / 6 (50.00%)	4 / 6 (66.67%)	5 / 6 (83.33%)
occurrences (all)	5	17	8
Mouth ulceration			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Aphthous ulcer			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Anorectal discomfort			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			

Papule			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Rash			
subjects affected / exposed	0 / 6 (0.00%)	2 / 6 (33.33%)	1 / 6 (16.67%)
occurrences (all)	0	5	2
Skin fissures			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hyperkeratosis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Rash papular			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Dermatitis atopic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Telangiectasia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Rash erythematous			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Skin lesion			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Eczema			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	1 / 6 (16.67%)
occurrences (all)	0	1	1
Rash maculo-papular			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1

<p>           Dermatitis contact            subjects affected / exposed            occurrences (all)         </p>	<p>           0 / 6 (0.00%)            0         </p>	<p>           0 / 6 (0.00%)            0         </p>	<p>           0 / 6 (0.00%)            0         </p>
<p>           Acne            subjects affected / exposed            occurrences (all)         </p>	<p>           1 / 6 (16.67%)            1         </p>	<p>           0 / 6 (0.00%)            0         </p>	<p>           0 / 6 (0.00%)            0         </p>
<p>           Eczema asteatotic            subjects affected / exposed            occurrences (all)         </p>	<p>           0 / 6 (0.00%)            0         </p>	<p>           0 / 6 (0.00%)            0         </p>	<p>           0 / 6 (0.00%)            0         </p>
<p>           Photosensitivity reaction            subjects affected / exposed            occurrences (all)         </p>	<p>           0 / 6 (0.00%)            0         </p>	<p>           0 / 6 (0.00%)            0         </p>	<p>           1 / 6 (16.67%)            1         </p>
<p>           Hirsutism            subjects affected / exposed            occurrences (all)         </p>	<p>           0 / 6 (0.00%)            0         </p>	<p>           0 / 6 (0.00%)            0         </p>	<p>           0 / 6 (0.00%)            0         </p>
<p>           Xeroderma            subjects affected / exposed            occurrences (all)         </p>	<p>           0 / 6 (0.00%)            0         </p>	<p>           0 / 6 (0.00%)            0         </p>	<p>           0 / 6 (0.00%)            0         </p>
<p>           Skin ulcer            subjects affected / exposed            occurrences (all)         </p>	<p>           0 / 6 (0.00%)            0         </p>	<p>           0 / 6 (0.00%)            0         </p>	<p>           0 / 6 (0.00%)            0         </p>
<p>           Onychomadesis            subjects affected / exposed            occurrences (all)         </p>	<p>           0 / 6 (0.00%)            0         </p>	<p>           0 / 6 (0.00%)            0         </p>	<p>           1 / 6 (16.67%)            1         </p>
<p>           Ingrowing nail            subjects affected / exposed            occurrences (all)         </p>	<p>           1 / 6 (16.67%)            2         </p>	<p>           0 / 6 (0.00%)            0         </p>	<p>           0 / 6 (0.00%)            0         </p>
<p>           Hand dermatitis            subjects affected / exposed            occurrences (all)         </p>	<p>           0 / 6 (0.00%)            0         </p>	<p>           0 / 6 (0.00%)            0         </p>	<p>           0 / 6 (0.00%)            0         </p>
<p>           Rash macular            subjects affected / exposed            occurrences (all)         </p>	<p>           0 / 6 (0.00%)            0         </p>	<p>           0 / 6 (0.00%)            0         </p>	<p>           1 / 6 (16.67%)            1         </p>
<p>           Miliaria            subjects affected / exposed            occurrences (all)         </p>	<p>           0 / 6 (0.00%)            0         </p>	<p>           0 / 6 (0.00%)            0         </p>	<p>           0 / 6 (0.00%)            0         </p>

Dandruff			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Skin mass			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Alopecia			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Hyperhidrosis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Seborrhoea			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Purpura			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dermatitis acneiform			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Dry skin			
subjects affected / exposed	2 / 6 (33.33%)	1 / 6 (16.67%)	2 / 6 (33.33%)
occurrences (all)	6	2	2
Erythema			
subjects affected / exposed	1 / 6 (16.67%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences (all)	2	1	0
Pityriasis alba			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Renal and urinary disorders			
Urinary incontinence			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	2
Urinary hesitation			

subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Acute kidney injury			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Urinary tract pain			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences (all)	0	2	0
Micturition urgency			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	1 / 6 (16.67%)
occurrences (all)	0	1	1
Pollakiuria			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	2
Urinary retention			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Polyuria			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dysuria			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Endocrine disorders			
Precocious puberty			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Musculoskeletal and connective tissue disorders			
Neck pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	2
Pain in extremity			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	2 / 6 (33.33%)
occurrences (all)	0	1	6
Back pain			

subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	2 / 6 (33.33%)
occurrences (all)	0	0	6
<b>Arthralgia</b>			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	4
<b>Groin pain</b>			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
<b>Muscle spasms</b>			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
<b>Joint swelling</b>			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
<b>Myalgia</b>			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
<b>Spinal deformity</b>			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
<b>Pain in jaw</b>			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
<b>Flank pain</b>			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
<b>Infections and infestations</b>			
<b>Scarlet fever</b>			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
<b>Upper respiratory tract infection</b>			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	1 / 6 (16.67%)
occurrences (all)	0	1	1
<b>Rhinitis</b>			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Catheter site infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Anorectal infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hand-foot-and-mouth disease			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Viral tonsillitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Viral infection			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	1	0	1
COVID-19			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Tonsillitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Fungal skin infection			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	1	0	1
Paronychia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Rash pustular			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	5

Varicella			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Bronchitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Respiratory tract infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Localised infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Rhinovirus infection			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Skin infection			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Ear infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Oral herpes			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
H1N1 influenza			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Folliculitis			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
Oral candidiasis			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences (all)	0	1	0

Nasopharyngitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Suspected COVID-19			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hordeolum			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Influenza			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	1	0	1
Impetigo			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Nail infection			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Otitis media			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pharyngitis			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Staphylococcal infection			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Metabolism and nutrition disorders			
Glucose tolerance impaired			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Hypoglycaemia			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Hyperglycaemia			

subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences (all)	0	3	0
<b>Hyperkalaemia</b>			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
<b>Dehydration</b>			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
<b>Hypophosphataemia</b>			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
<b>Hypoalbuminaemia</b>			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
<b>Hypomagnesaemia</b>			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
<b>Hypokalaemia</b>			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences (all)	0	4	0
<b>Hyponatraemia</b>			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
<b>Hypernatraemia</b>			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
<b>Hyperuricaemia</b>			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
<b>Decreased appetite</b>			
subjects affected / exposed	1 / 6 (16.67%)	1 / 6 (16.67%)	2 / 6 (33.33%)
occurrences (all)	1	1	2

<b>Non-serious adverse events</b>	Phase I (Suspension) Cobimetinib (0.6 mg/kg)	Phase I (Suspension) Cobimetinib (1 mg/kg)	Phase I (Suspension) Cobimetinib (0.8 mg/kg)
Total subjects affected by non-serious			

adverse events			
subjects affected / exposed	6 / 6 (100.00%)	8 / 8 (100.00%)	7 / 7 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Skin papilloma			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Hair follicle tumour benign			
subjects affected / exposed	1 / 6 (16.67%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
General disorders and administration site conditions			
Gait disturbance			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Chest pain			
subjects affected / exposed	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 7 (0.00%)
occurrences (all)	0	2	0
Fatigue			
subjects affected / exposed	2 / 6 (33.33%)	3 / 8 (37.50%)	2 / 7 (28.57%)
occurrences (all)	2	3	3
Inflammation			
subjects affected / exposed	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Localised oedema			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Oedema peripheral			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Xerosis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Nodule			

subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
<b>Asthenia</b> subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
<b>Mucosal inflammation</b> subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 8 (12.50%) 1	0 / 7 (0.00%) 0
<b>Extravasation</b> subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
<b>Malaise</b> subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 8 (12.50%) 1	0 / 7 (0.00%) 0
<b>Pyrexia</b> subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	2 / 8 (25.00%) 2	1 / 7 (14.29%) 1
<b>Immune system disorders</b> <b>Hypersensitivity</b> subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
<b>Reproductive system and breast disorders</b> <b>Balanoposthitis</b> subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
<b>Scrotal ulcer</b> subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
<b>Vulvovaginal pain</b> subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
<b>Respiratory, thoracic and mediastinal disorders</b> <b>Epistaxis</b> subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 8 (0.00%) 0	1 / 7 (14.29%) 1
<b>Dyspnoea</b>			

subjects affected / exposed	0 / 6 (0.00%)	2 / 8 (25.00%)	0 / 7 (0.00%)
occurrences (all)	0	2	0
Nasal congestion			
subjects affected / exposed	2 / 6 (33.33%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	2	0	0
Pleural effusion			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Pneumonia aspiration			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Cough			
subjects affected / exposed	2 / 6 (33.33%)	1 / 8 (12.50%)	1 / 7 (14.29%)
occurrences (all)	2	1	1
Sputum decreased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Insomnia			
subjects affected / exposed	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Behaviour disorder			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Anxiety			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Inappropriate affect			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0

Bradyphrenia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
<b>Investigations</b>			
Blood bicarbonate decreased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Ejection fraction decreased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 8 (12.50%) 3	1 / 7 (14.29%) 1
Blood alkaline phosphatase increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Blood chloride increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
White blood cell count decreased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0	2 / 7 (28.57%) 3
Blood creatinine decreased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Electrocardiogram QT prolonged subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Anion gap increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Lymphocyte count decreased subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 4	1 / 8 (12.50%) 1	1 / 7 (14.29%) 1
Weight decreased			

subjects affected / exposed	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Body temperature decreased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Platelet count increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Cortisol decreased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Intraocular pressure increased			
subjects affected / exposed	1 / 6 (16.67%)	0 / 8 (0.00%)	1 / 7 (14.29%)
occurrences (all)	1	0	1
Neutrophil count decreased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	2 / 7 (28.57%)
occurrences (all)	0	0	3
Transaminases increased			
subjects affected / exposed	1 / 6 (16.67%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	2	0	0
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Protein total decreased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Blood creatinine increased			
subjects affected / exposed	0 / 6 (0.00%)	1 / 8 (12.50%)	1 / 7 (14.29%)
occurrences (all)	0	1	1
Mean cell volume increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Lymphocyte count increased			
subjects affected / exposed	1 / 6 (16.67%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0

Blood creatine phosphokinase increased subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	1 / 8 (12.50%) 1	2 / 7 (28.57%) 3
White blood cell count increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Body temperature increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Oxygen saturation decreased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Weight increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Blood cholesterol increased subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Platelet count decreased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Neutrophil count increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Injury, poisoning and procedural complications			
Skin abrasion subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 8 (12.50%) 1	1 / 7 (14.29%) 1
Face injury subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Thermal burn			

subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Wrist fracture			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Foreign body in ear			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Hand fracture			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Contusion			
subjects affected / exposed	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Limb injury			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Arthropod bite			
subjects affected / exposed	1 / 6 (16.67%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Ligament sprain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Foot fracture			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Head injury			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Skin laceration			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Tooth fracture			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Fall			

subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 8 (12.50%) 1	0 / 7 (0.00%) 0
Abdominal injury subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Skin wound subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Congenital, familial and genetic disorders Iris hamartoma subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Cardiac disorders Sinus tachycardia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0	1 / 7 (14.29%) 2
Nervous system disorders Headache subjects affected / exposed occurrences (all)	2 / 6 (33.33%) 4	4 / 8 (50.00%) 4	3 / 7 (42.86%) 8
Dizziness subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Paraesthesia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Tremor subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	2 / 8 (25.00%) 2	0 / 7 (0.00%) 0
Lethargy subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Sciatica subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Neuralgia			

subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0	1 / 7 (14.29%) 1
<b>Blood and lymphatic system disorders</b>			
Thrombocytopenia			
subjects affected / exposed	1 / 6 (16.67%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Leukopenia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Anaemia			
subjects affected / exposed	1 / 6 (16.67%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	3	0	0
Lymphadenopathy			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
<b>Ear and labyrinth disorders</b>			
Ear pain			
subjects affected / exposed	1 / 6 (16.67%)	2 / 8 (25.00%)	0 / 7 (0.00%)
occurrences (all)	1	3	0
<b>Eye disorders</b>			
Retinal detachment			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Vision blurred			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Conjunctivitis allergic			
subjects affected / exposed	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Ocular hyperaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Punctate keratitis			
subjects affected / exposed	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Ocular hypertension			

subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Miosis			
subjects affected / exposed	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Detachment of retinal pigment epithelium			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Optic disc disorder			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Visual acuity reduced transiently			
subjects affected / exposed	1 / 6 (16.67%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Serous retinal detachment			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Retinal disorder			
subjects affected / exposed	1 / 6 (16.67%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Corneal neovascularisation			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Optic atrophy			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Dry eye			
subjects affected / exposed	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Visual impairment			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Eye pain			
subjects affected / exposed	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 7 (0.00%)
occurrences (all)	0	1	0

Eye disorder			
subjects affected / exposed	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Visual field defect			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Eyelid skin dryness			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Eyelid ptosis			
subjects affected / exposed	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Chorioretinopathy			
subjects affected / exposed	1 / 6 (16.67%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Gastrointestinal disorders			
Toothache			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Dyspepsia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Tongue ulceration			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Abdominal pain upper			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Lip haemorrhage			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	2 / 6 (33.33%)	4 / 8 (50.00%)	2 / 7 (28.57%)
occurrences (all)	2	7	9
Anal haemorrhage			

subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	0 / 6 (0.00%)	2 / 8 (25.00%)	0 / 7 (0.00%)
occurrences (all)	0	3	0
Lip ulceration			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Dysphagia			
subjects affected / exposed	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Glossodynia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Oesophagitis			
subjects affected / exposed	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Haematochezia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Proctalgia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Dry mouth			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	0 / 6 (0.00%)	3 / 8 (37.50%)	2 / 7 (28.57%)
occurrences (all)	0	5	7
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Gastritis			
subjects affected / exposed	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Dental caries			

subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Abdominal distension			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Stomatitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Faeces hard			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Tooth impacted			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Abdominal pain			
subjects affected / exposed	1 / 6 (16.67%)	1 / 8 (12.50%)	2 / 7 (28.57%)
occurrences (all)	1	1	2
Diarrhoea			
subjects affected / exposed	4 / 6 (66.67%)	4 / 8 (50.00%)	2 / 7 (28.57%)
occurrences (all)	6	6	3
Mouth ulceration			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Aphthous ulcer			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Anorectal discomfort			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Skin and subcutaneous tissue disorders			
Papule			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	1 / 6 (16.67%)	1 / 8 (12.50%)	2 / 7 (28.57%)
occurrences (all)	1	1	2

Skin fissures			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Hyperkeratosis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Pruritus			
subjects affected / exposed	1 / 6 (16.67%)	1 / 8 (12.50%)	0 / 7 (0.00%)
occurrences (all)	1	1	0
Rash papular			
subjects affected / exposed	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Dermatitis atopic			
subjects affected / exposed	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Telangiectasia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Rash erythematous			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Skin lesion			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Eczema			
subjects affected / exposed	1 / 6 (16.67%)	1 / 8 (12.50%)	1 / 7 (14.29%)
occurrences (all)	1	1	1
Rash maculo-papular			
subjects affected / exposed	1 / 6 (16.67%)	1 / 8 (12.50%)	0 / 7 (0.00%)
occurrences (all)	1	5	0
Dermatitis contact			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Acne			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1

Eczema asteatotic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Photosensitivity reaction			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Hirsutism			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Xeroderma			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Skin ulcer			
subjects affected / exposed	1 / 6 (16.67%)	0 / 8 (0.00%)	1 / 7 (14.29%)
occurrences (all)	1	0	1
Onychomadesis			
subjects affected / exposed	1 / 6 (16.67%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Ingrowing nail			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Hand dermatitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Rash macular			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Miliaria			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Dandruff			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Skin mass			
subjects affected / exposed	1 / 6 (16.67%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0

Alopecia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Hyperhidrosis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Seborrhoea			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Purpura			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Dermatitis acneiform			
subjects affected / exposed	1 / 6 (16.67%)	1 / 8 (12.50%)	1 / 7 (14.29%)
occurrences (all)	1	1	1
Dry skin			
subjects affected / exposed	0 / 6 (0.00%)	2 / 8 (25.00%)	3 / 7 (42.86%)
occurrences (all)	0	2	3
Erythema			
subjects affected / exposed	1 / 6 (16.67%)	0 / 8 (0.00%)	1 / 7 (14.29%)
occurrences (all)	1	0	1
Pityriasis alba			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Urinary incontinence			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Urinary hesitation			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Acute kidney injury			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Urinary tract pain			

subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Micturition urgency			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Pollakiuria			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Urinary retention			
subjects affected / exposed	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Polyuria			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Dysuria			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Endocrine disorders			
Precocious puberty			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Neck pain			
subjects affected / exposed	0 / 6 (0.00%)	1 / 8 (12.50%)	2 / 7 (28.57%)
occurrences (all)	0	1	2
Pain in extremity			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	2 / 7 (28.57%)
occurrences (all)	0	0	3
Back pain			
subjects affected / exposed	0 / 6 (0.00%)	2 / 8 (25.00%)	1 / 7 (14.29%)
occurrences (all)	0	2	1
Arthralgia			
subjects affected / exposed	1 / 6 (16.67%)	2 / 8 (25.00%)	0 / 7 (0.00%)
occurrences (all)	1	2	0
Groin pain			

subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Muscle spasms			
subjects affected / exposed	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Joint swelling			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Myalgia			
subjects affected / exposed	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Spinal deformity			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Pain in jaw			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Flank pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Scarlet fever			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Upper respiratory tract infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Rhinitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Catheter site infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Anorectal infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0

Hand-foot-and-mouth disease subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Conjunctivitis subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 8 (12.50%) 1	0 / 7 (0.00%) 0
Viral tonsillitis subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Viral infection subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 8 (12.50%) 1	0 / 7 (0.00%) 0
COVID-19 subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Tonsillitis subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Fungal skin infection subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Paronychia subjects affected / exposed occurrences (all)	2 / 6 (33.33%) 2	1 / 8 (12.50%) 1	1 / 7 (14.29%) 1
Rash pustular subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 8 (12.50%) 1	0 / 7 (0.00%) 0
Urinary tract infection subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Varicella subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 8 (12.50%) 1	1 / 7 (14.29%) 1
Bronchitis subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0

Respiratory tract infection subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Localised infection subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Rhinovirus infection subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Skin infection subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 8 (12.50%) 1	0 / 7 (0.00%) 0
Ear infection subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 8 (12.50%) 1	1 / 7 (14.29%) 1
Viral upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Oral herpes subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 8 (12.50%) 1	0 / 7 (0.00%) 0
H1N1 influenza subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Folliculitis subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 8 (0.00%) 0	1 / 7 (14.29%) 1
Oral candidiasis subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Nasopharyngitis subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0	1 / 7 (14.29%) 1
Suspected COVID-19 subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0

Hordeolum			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Influenza			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Impetigo			
subjects affected / exposed	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 7 (0.00%)
occurrences (all)	0	2	0
Nail infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Otitis media			
subjects affected / exposed	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Pharyngitis			
subjects affected / exposed	0 / 6 (0.00%)	1 / 8 (12.50%)	0 / 7 (0.00%)
occurrences (all)	0	2	0
Staphylococcal infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Glucose tolerance impaired			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Hypoglycaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Hyperglycaemia			
subjects affected / exposed	1 / 6 (16.67%)	0 / 8 (0.00%)	1 / 7 (14.29%)
occurrences (all)	1	0	1
Hyperkalaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Dehydration			

subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Hypophosphataemia			
subjects affected / exposed	1 / 6 (16.67%)	0 / 8 (0.00%)	1 / 7 (14.29%)
occurrences (all)	1	0	1
Hypoalbuminaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Hypomagnesaemia			
subjects affected / exposed	1 / 6 (16.67%)	0 / 8 (0.00%)	2 / 7 (28.57%)
occurrences (all)	5	0	2
Hypokalaemia			
subjects affected / exposed	2 / 6 (33.33%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	6	0	0
Hyponatraemia			
subjects affected / exposed	1 / 6 (16.67%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	5	0	0
Hypernatraemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Hyperuricaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Decreased appetite			
subjects affected / exposed	0 / 6 (0.00%)	2 / 8 (25.00%)	2 / 7 (28.57%)
occurrences (all)	0	2	2

	Phase I (Suspension) Cobimetinib (1.33 mg/kg)	Phase II (Suspension) Cobimetinib (1 mg/kg)	
<b>Non-serious adverse events</b>			
Total subjects affected by non-serious adverse events			
subjects affected / exposed	5 / 5 (100.00%)	12 / 12 (100.00%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Skin papilloma			
subjects affected / exposed	0 / 5 (0.00%)	1 / 12 (8.33%)	
occurrences (all)	0	1	
Hair follicle tumour benign			

subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 12 (0.00%) 0	
Vascular disorders Hypertension subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 12 (8.33%) 1	
General disorders and administration site conditions Gait disturbance subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 12 (0.00%) 0	
Chest pain subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 12 (0.00%) 0	
Fatigue subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	2 / 12 (16.67%) 2	
Inflammation subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 12 (0.00%) 0	
Localised oedema subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 12 (0.00%) 0	
Oedema peripheral subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 12 (8.33%) 1	
Xerosis subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 12 (0.00%) 0	
Nodule subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 12 (0.00%) 0	
Asthenia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 12 (8.33%) 2	
Mucosal inflammation			

subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 12 (0.00%) 0	
Extravasation subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 12 (0.00%) 0	
Malaise subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 12 (0.00%) 0	
Pyrexia subjects affected / exposed occurrences (all)	2 / 5 (40.00%) 3	3 / 12 (25.00%) 5	
Immune system disorders Hypersensitivity subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 12 (0.00%) 0	
Reproductive system and breast disorders Balanoposthitis subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 12 (0.00%) 0	
Scrotal ulcer subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 12 (0.00%) 0	
Vulvovaginal pain subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 12 (8.33%) 1	
Respiratory, thoracic and mediastinal disorders Epistaxis subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	4 / 12 (33.33%) 5	
Dyspnoea subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 12 (0.00%) 0	
Nasal congestion subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 12 (8.33%) 1	
Pleural effusion			

subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)	
occurrences (all)	0	0	
Oropharyngeal pain			
subjects affected / exposed	1 / 5 (20.00%)	1 / 12 (8.33%)	
occurrences (all)	1	1	
Rhinorrhoea			
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)	
occurrences (all)	0	0	
Pneumonia aspiration			
subjects affected / exposed	0 / 5 (0.00%)	1 / 12 (8.33%)	
occurrences (all)	0	1	
Cough			
subjects affected / exposed	0 / 5 (0.00%)	3 / 12 (25.00%)	
occurrences (all)	0	5	
Sputum decreased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)	
occurrences (all)	0	0	
Psychiatric disorders			
Insomnia			
subjects affected / exposed	1 / 5 (20.00%)	0 / 12 (0.00%)	
occurrences (all)	1	0	
Behaviour disorder			
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)	
occurrences (all)	0	0	
Anxiety			
subjects affected / exposed	1 / 5 (20.00%)	0 / 12 (0.00%)	
occurrences (all)	1	0	
Inappropriate affect			
subjects affected / exposed	0 / 5 (0.00%)	1 / 12 (8.33%)	
occurrences (all)	0	2	
Bradyphrenia			
subjects affected / exposed	0 / 5 (0.00%)	1 / 12 (8.33%)	
occurrences (all)	0	1	
Investigations			
Blood bicarbonate decreased			

subjects affected / exposed	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	2
Ejection fraction decreased		
subjects affected / exposed	1 / 5 (20.00%)	0 / 12 (0.00%)
occurrences (all)	1	0
Blood alkaline phosphatase increased		
subjects affected / exposed	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	2
Blood chloride increased		
subjects affected / exposed	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	3
Aspartate aminotransferase increased		
subjects affected / exposed	1 / 5 (20.00%)	1 / 12 (8.33%)
occurrences (all)	2	1
White blood cell count decreased		
subjects affected / exposed	0 / 5 (0.00%)	2 / 12 (16.67%)
occurrences (all)	0	8
Blood creatinine decreased		
subjects affected / exposed	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	1
Electrocardiogram QT prolonged		
subjects affected / exposed	1 / 5 (20.00%)	0 / 12 (0.00%)
occurrences (all)	2	0
Anion gap increased		
subjects affected / exposed	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	3
Lymphocyte count decreased		
subjects affected / exposed	0 / 5 (0.00%)	2 / 12 (16.67%)
occurrences (all)	0	4
Weight decreased		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Body temperature decreased		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0

Platelet count increased		
subjects affected / exposed	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	2
Cortisol decreased		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Intraocular pressure increased		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Neutrophil count decreased		
subjects affected / exposed	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	5
Transaminases increased		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Gamma-glutamyltransferase increased		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Protein total decreased		
subjects affected / exposed	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	3
Blood creatinine increased		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Mean cell volume increased		
subjects affected / exposed	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	1
Lymphocyte count increased		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Blood creatine phosphokinase increased		
subjects affected / exposed	0 / 5 (0.00%)	4 / 12 (33.33%)
occurrences (all)	0	8
White blood cell count increased		

subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 12 (0.00%) 0	
Body temperature increased subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 12 (0.00%) 0	
Oxygen saturation decreased subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 12 (0.00%) 0	
Weight increased subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	2 / 12 (16.67%) 2	
Blood cholesterol increased subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 12 (0.00%) 0	
Platelet count decreased subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 12 (8.33%) 1	
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	2 / 5 (40.00%) 3	0 / 12 (0.00%) 0	
Neutrophil count increased subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	1 / 12 (8.33%) 1	
Injury, poisoning and procedural complications			
Skin abrasion subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 12 (8.33%) 1	
Face injury subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 12 (0.00%) 0	
Thermal burn subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 12 (8.33%) 1	
Wrist fracture			

subjects affected / exposed	1 / 5 (20.00%)	1 / 12 (8.33%)
occurrences (all)	1	1
Foreign body in ear		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Hand fracture		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Contusion		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Limb injury		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Arthropod bite		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Ligament sprain		
subjects affected / exposed	1 / 5 (20.00%)	0 / 12 (0.00%)
occurrences (all)	1	0
Foot fracture		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Head injury		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Skin laceration		
subjects affected / exposed	1 / 5 (20.00%)	0 / 12 (0.00%)
occurrences (all)	1	0
Tooth fracture		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Fall		
subjects affected / exposed	1 / 5 (20.00%)	1 / 12 (8.33%)
occurrences (all)	1	1
Abdominal injury		

subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 12 (0.00%) 0	
Skin wound subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 12 (0.00%) 0	
Congenital, familial and genetic disorders Iris hamartoma subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 12 (0.00%) 0	
Cardiac disorders Sinus tachycardia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 12 (0.00%) 0	
Nervous system disorders Headache subjects affected / exposed occurrences (all)	3 / 5 (60.00%) 5	7 / 12 (58.33%) 11	
Dizziness subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 12 (0.00%) 0	
Paraesthesia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 12 (0.00%) 0	
Tremor subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 12 (0.00%) 0	
Lethargy subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 12 (0.00%) 0	
Sciatica subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 12 (0.00%) 0	
Neuralgia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 12 (0.00%) 0	
Blood and lymphatic system disorders			

Thrombocytopenia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 12 (0.00%) 0	
Leukopenia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 12 (8.33%) 1	
Anaemia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	3 / 12 (25.00%) 6	
Lymphadenopathy subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 12 (0.00%) 0	
Ear and labyrinth disorders Ear pain subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	2 / 12 (16.67%) 2	
Eye disorders Retinal detachment subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 12 (0.00%) 0	
Vision blurred subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 12 (0.00%) 0	
Conjunctivitis allergic subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 12 (0.00%) 0	
Ocular hyperaemia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 12 (0.00%) 0	
Punctate keratitis subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 12 (8.33%) 1	
Ocular hypertension subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 12 (0.00%) 0	
Miosis			

subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Detachment of retinal pigment epithelium		
subjects affected / exposed	1 / 5 (20.00%)	0 / 12 (0.00%)
occurrences (all)	1	0
Optic disc disorder		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Visual acuity reduced transiently		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Serous retinal detachment		
subjects affected / exposed	1 / 5 (20.00%)	0 / 12 (0.00%)
occurrences (all)	2	0
Retinal disorder		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Corneal neovascularisation		
subjects affected / exposed	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	1
Optic atrophy		
subjects affected / exposed	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	1
Dry eye		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Visual impairment		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Eye pain		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Eye disorder		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0

Visual field defect			
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)	
occurrences (all)	0	0	
Eyelid skin dryness			
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)	
occurrences (all)	0	0	
Eyelid ptosis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)	
occurrences (all)	0	0	
Chorioretinopathy			
subjects affected / exposed	1 / 5 (20.00%)	0 / 12 (0.00%)	
occurrences (all)	1	0	
Gastrointestinal disorders			
Toothache			
subjects affected / exposed	0 / 5 (0.00%)	1 / 12 (8.33%)	
occurrences (all)	0	1	
Dyspepsia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)	
occurrences (all)	0	0	
Tongue ulceration			
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)	
occurrences (all)	0	0	
Abdominal pain upper			
subjects affected / exposed	1 / 5 (20.00%)	1 / 12 (8.33%)	
occurrences (all)	4	2	
Lip haemorrhage			
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)	
occurrences (all)	0	0	
Vomiting			
subjects affected / exposed	2 / 5 (40.00%)	7 / 12 (58.33%)	
occurrences (all)	2	14	
Anal haemorrhage			
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)	
occurrences (all)	0	0	
Constipation			

subjects affected / exposed	1 / 5 (20.00%)	3 / 12 (25.00%)
occurrences (all)	1	3
Lip ulceration		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Dysphagia		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Glossodynia		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Oesophagitis		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Haematochezia		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Proctalgia		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Dry mouth		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Nausea		
subjects affected / exposed	0 / 5 (0.00%)	2 / 12 (16.67%)
occurrences (all)	0	2
Gastrooesophageal reflux disease		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Gastritis		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Dental caries		
subjects affected / exposed	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	1
Abdominal distension		

subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)	
occurrences (all)	0	0	
Stomatitis			
subjects affected / exposed	1 / 5 (20.00%)	0 / 12 (0.00%)	
occurrences (all)	1	0	
Faeces hard			
subjects affected / exposed	0 / 5 (0.00%)	1 / 12 (8.33%)	
occurrences (all)	0	1	
Tooth impacted			
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)	
occurrences (all)	0	0	
Abdominal pain			
subjects affected / exposed	2 / 5 (40.00%)	3 / 12 (25.00%)	
occurrences (all)	2	7	
Diarrhoea			
subjects affected / exposed	4 / 5 (80.00%)	4 / 12 (33.33%)	
occurrences (all)	10	11	
Mouth ulceration			
subjects affected / exposed	1 / 5 (20.00%)	0 / 12 (0.00%)	
occurrences (all)	1	0	
Aphthous ulcer			
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)	
occurrences (all)	0	0	
Anorectal discomfort			
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)	
occurrences (all)	0	0	
Skin and subcutaneous tissue disorders			
Papule			
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)	
occurrences (all)	0	0	
Rash			
subjects affected / exposed	1 / 5 (20.00%)	2 / 12 (16.67%)	
occurrences (all)	1	2	
Skin fissures			
subjects affected / exposed	1 / 5 (20.00%)	0 / 12 (0.00%)	
occurrences (all)	1	0	

Hyperkeratosis		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Pruritus		
subjects affected / exposed	1 / 5 (20.00%)	0 / 12 (0.00%)
occurrences (all)	1	0
Rash papular		
subjects affected / exposed	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	2
Dermatitis atopic		
subjects affected / exposed	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	1
Telangiectasia		
subjects affected / exposed	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	1
Rash erythematous		
subjects affected / exposed	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	1
Skin lesion		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Eczema		
subjects affected / exposed	0 / 5 (0.00%)	2 / 12 (16.67%)
occurrences (all)	0	2
Rash maculo-papular		
subjects affected / exposed	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	1
Dermatitis contact		
subjects affected / exposed	1 / 5 (20.00%)	0 / 12 (0.00%)
occurrences (all)	1	0
Acne		
subjects affected / exposed	1 / 5 (20.00%)	0 / 12 (0.00%)
occurrences (all)	1	0
Eczema asteatotic		
subjects affected / exposed	1 / 5 (20.00%)	0 / 12 (0.00%)
occurrences (all)	1	0

Photosensitivity reaction		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Hirsutism		
subjects affected / exposed	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	1
Xeroderma		
subjects affected / exposed	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	1
Skin ulcer		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Onychomadesis		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Ingrowing nail		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Hand dermatitis		
subjects affected / exposed	1 / 5 (20.00%)	0 / 12 (0.00%)
occurrences (all)	1	0
Rash macular		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Miliaria		
subjects affected / exposed	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	1
Dandruff		
subjects affected / exposed	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	2
Skin mass		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Alopecia		
subjects affected / exposed	1 / 5 (20.00%)	0 / 12 (0.00%)
occurrences (all)	1	0

Hyperhidrosis			
subjects affected / exposed	0 / 5 (0.00%)	1 / 12 (8.33%)	
occurrences (all)	0	1	
Seborrhoea			
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)	
occurrences (all)	0	0	
Purpura			
subjects affected / exposed	0 / 5 (0.00%)	1 / 12 (8.33%)	
occurrences (all)	0	2	
Dermatitis acneiform			
subjects affected / exposed	3 / 5 (60.00%)	1 / 12 (8.33%)	
occurrences (all)	3	1	
Dry skin			
subjects affected / exposed	1 / 5 (20.00%)	1 / 12 (8.33%)	
occurrences (all)	2	1	
Erythema			
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)	
occurrences (all)	0	0	
Pityriasis alba			
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)	
occurrences (all)	0	0	
Renal and urinary disorders			
Urinary incontinence			
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)	
occurrences (all)	0	0	
Urinary hesitation			
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)	
occurrences (all)	0	0	
Acute kidney injury			
subjects affected / exposed	0 / 5 (0.00%)	1 / 12 (8.33%)	
occurrences (all)	0	2	
Urinary tract pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)	
occurrences (all)	0	0	
Micturition urgency			

subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 12 (0.00%) 0	
Pollakiuria subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 12 (8.33%) 1	
Urinary retention subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 12 (0.00%) 0	
Polyuria subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 12 (0.00%) 0	
Dysuria subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 12 (8.33%) 1	
Endocrine disorders Precocious puberty subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 12 (0.00%) 0	
Musculoskeletal and connective tissue disorders Neck pain subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 12 (0.00%) 0	
Pain in extremity subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 12 (0.00%) 0	
Back pain subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 12 (0.00%) 0	
Arthralgia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 12 (0.00%) 0	
Groin pain subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 12 (0.00%) 0	
Muscle spasms			

subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 12 (0.00%) 0	
Joint swelling subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 12 (0.00%) 0	
Myalgia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 12 (0.00%) 0	
Spinal deformity subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 12 (0.00%) 0	
Pain in jaw subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 12 (0.00%) 0	
Flank pain subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 12 (0.00%) 0	
Infections and infestations			
Scarlet fever subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 12 (0.00%) 0	
Upper respiratory tract infection subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	2 / 12 (16.67%) 2	
Rhinitis subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 12 (0.00%) 0	
Catheter site infection subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	1 / 12 (8.33%) 1	
Anorectal infection subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 12 (8.33%) 1	
Hand-foot-and-mouth disease subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 12 (0.00%) 0	

Conjunctivitis		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Viral tonsillitis		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Viral infection		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
COVID-19		
subjects affected / exposed	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	1
Tonsillitis		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Fungal skin infection		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Paronychia		
subjects affected / exposed	1 / 5 (20.00%)	2 / 12 (16.67%)
occurrences (all)	1	2
Rash pustular		
subjects affected / exposed	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	1
Urinary tract infection		
subjects affected / exposed	1 / 5 (20.00%)	0 / 12 (0.00%)
occurrences (all)	2	0
Varicella		
subjects affected / exposed	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	1
Bronchitis		
subjects affected / exposed	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	1
Respiratory tract infection		
subjects affected / exposed	0 / 5 (0.00%)	2 / 12 (16.67%)
occurrences (all)	0	2

Localised infection		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Rhinovirus infection		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Skin infection		
subjects affected / exposed	1 / 5 (20.00%)	0 / 12 (0.00%)
occurrences (all)	2	0
Ear infection		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Viral upper respiratory tract infection		
subjects affected / exposed	1 / 5 (20.00%)	0 / 12 (0.00%)
occurrences (all)	1	0
Oral herpes		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
H1N1 influenza		
subjects affected / exposed	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	1
Folliculitis		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Oral candidiasis		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Nasopharyngitis		
subjects affected / exposed	0 / 5 (0.00%)	2 / 12 (16.67%)
occurrences (all)	0	2
Suspected COVID-19		
subjects affected / exposed	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	1
Hordeolum		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0

Influenza			
subjects affected / exposed	1 / 5 (20.00%)	1 / 12 (8.33%)	
occurrences (all)	1	1	
Impetigo			
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)	
occurrences (all)	0	0	
Nail infection			
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)	
occurrences (all)	0	0	
Otitis media			
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)	
occurrences (all)	0	0	
Pharyngitis			
subjects affected / exposed	0 / 5 (0.00%)	1 / 12 (8.33%)	
occurrences (all)	0	1	
Staphylococcal infection			
subjects affected / exposed	1 / 5 (20.00%)	0 / 12 (0.00%)	
occurrences (all)	1	0	
Metabolism and nutrition disorders			
Glucose tolerance impaired			
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)	
occurrences (all)	0	0	
Hypoglycaemia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)	
occurrences (all)	0	0	
Hyperglycaemia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)	
occurrences (all)	0	0	
Hyperkalaemia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)	
occurrences (all)	0	0	
Dehydration			
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)	
occurrences (all)	0	0	
Hypophosphataemia			

subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Hypoalbuminaemia		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Hypomagnesaemia		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Hypokalaemia		
subjects affected / exposed	1 / 5 (20.00%)	0 / 12 (0.00%)
occurrences (all)	1	0
Hyponatraemia		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Hypernatraemia		
subjects affected / exposed	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0
Hyperuricaemia		
subjects affected / exposed	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	2
Decreased appetite		
subjects affected / exposed	1 / 5 (20.00%)	1 / 12 (8.33%)
occurrences (all)	1	1

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
18 May 2015	Following updates were made: [1] Addition of complete rationale for using both tablet and liquid formulations; [2] Modification of guidance regarding frequency and nature of ophthalmology examinations; [3] Clarification of PK Outcome Measure; [4] Updates to Inclusion/Exclusion Criteria and [5] Addition of Safety Analysis.
05 August 2015	Following updates were made: [1] Removal of Liquid Formulation from study, so only Tablet Formulation to be kept; [2] Addition of Enrolment restrictions; [3] Modification of Dose Escalation rules; [4] Change in Starting Dose of Dose Escalation from 0.8 mg/kg/day to 0.6 mg/kg/day and [5] Dose-Limiting Toxicity (DLT) updates.
02 February 2016	Following updates were made: [1] Removal of references to perception of clinical benefit; [2] Updating of cardiac function DLT rules; [3] Updating of Inpatient dose escalation guidance and [4] Clarification of Dose reduction guidance.
15 June 2016	Following updates were made: [1] Addition of new Suspension Formulation; [2] Updates to Safety Information regarding Cobimetinib and [3] Additional Study Changes.
03 November 2016	Following updates were made: [1] Updated to align with most current available data with regards to the risks associated to Cobimetinib; [2] Updates to list of defined DLTs during the Dose Escalation phase; [3] Addition of new Eligibility Criteria; [4] Modification to International Neuroblastoma Response Criteria (INRC) used in this study; [5] Clarification of de-escalation rules and [6] Clarifications to Appendix 1.
07 February 2017	Following updates were made: [1] Restoration of dose modification guidance; [2] Clarification to Inclusion criteria and [3] Additional information relating to intracerebral hemorrhage.
10 May 2017	Following updates were made: [1] Revisions made to determination of the Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of each Cobimetinib formulation (tablet and suspension); [2] Clarification that enrolment of expansion cohorts may begin only after the IMC has reviewed pharmacokinetic (PK) and safety data and [3] Updates to include rationale for requiring a separate suspension dose escalation beginning at one level below that of the tablet MTD/MAD.
09 May 2018	Following updates were made: [1] Incorporation of Response Assessment in Neuro-Oncology (RANO) criteria for LGG; [2] Update to Inclusion Criteria; [3] Number of Study Subjects increased to approximately 70; [4] Updates to the interim efficacy analyses; [5] Updates to study stopping rules; [6] Clarification to Exclusion Criteria and [7] Updates to Appendix 5 and 10.
06 July 2018	Following update was made: [1] The objective response rate (ORR) for low-grade glioma (LGG) incorporating minor response, has been made an exploratory endpoint.
11 April 2019	Following updates were made: [1] Reduction in the frequency of tumor assessments for subjects who have completed at least 12 cycles of Cobimetinib therapy; [2] Plasma samples collection updated to align with the new tumor assessments schedule; [3] Reduction in the frequency of ophthalmologic examinations for subjects who have completed 6 cycles of Cobimetinib therapy and [4] Updates to Appendix 1 and 10.

---

Notes:

---

### **Interruptions (globally)**

Were there any global interruptions to the trial? No

### **Limitations and caveats**

None reported